Title: Study for Comparison of Iron Sucrose & Iron Sorbitol Citrate in Fixed Doses in Iron Deficiency Anemia during Pregnancy in a Tertiary Care Center
Authors: Dr Dev N. Shukla, Dr Badri Lal Patidar Dr Mamta Sharma, Dr Shivraj Meena
DOI: https://dx.doi.org/10.18535/jmscr/v5i3.147
Abstract
Background: Anemia is one of the most commonly encountered medical disorders in pregnancy & Iron deficiency is the leading cause of anemia in pregnancy. Aim of the study was to assess the efficacy of Iron Sucrose and Iron Sorbitol Citric Acid & to assess the safety and tolerability of these drugs in pregnant women with moderate anemia.
Methods: In this study, 100 antenatal cases of gestational age 14-32 weeks with hemoglobin 7-9 gm/dl were randomly divided into two groups of 50 each, which received a fixed dose of IV Iron Sucrose (Group A) & IM Iron Sorbitol Citric Acid therapy (Group B). The efficacy of the therapy was assessed by laboratory parameters such as hemoglobin, hematocrit, MCV, MCH, MCHC and serum ferritin level after 14 and 28 days. To assess the safety, adverse drug reactions with both the therapies were recorded.
Results: Pretreatment hemoglobin was 7.6±0.35 gm/dl & 7.6±0.31 gm/dl in Group A & B respectively. Hemoglobin concentration increased significantly (P<0.001), increase in Hb after 4 weeks of starting therapy was 1.2 gm/dl & 0.5 gm/dl in Group A & Group B respectively. Rise in other parameters (MCV, Ferritin etc) although were minimal but more in IV Group & statistically significant (p<0.05). Adverse events were more common with Iron Sorbitol Citric Acid therapy.
Conclusion: Intravenous therapy appears to be safer, faster, effective & more convenient than Intramuscular therapy in treatment of Iron deficiency anemia during pregnancy.
Keywords: Sorbitol, Sucrose, ferritin, Anemia, Pregnancy.
References
1. http://www.webmd.com/a-to-z-guides/understanding-anemia-basics.
2. Dutta Dc. 1. Anaemia in pregnancy. Text book of obstetrics including perinatology & contraception, 6th ed. Calcutta: New Central Book Agency (P) Ltd.; 2004. p. 262-7.
3. Ezzati M, Lopus AD, Dogers A, Vander HS, Murray C. 2. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360 : 1347-60.
4. National Family Health Survey 4 (2015-2016) http://rchiips.org/NFHS/NFHS4-/manual/NFHS-4%20Biomarker%20Field%20Manual.pdf
5. Scholl TO. Iron status during pregnancy: setting the stage for mother and infant. Am J Clin Nutr. 2005 May; 81(5): 1218 S-1222S.
6. National Rural Health Mission. Guidelines for control of Iron deficiency anaemia.2013; 6-30.
7. Dhanani J V, Ganguly B.P, Chauhan L.N. Comparison of efficacy and safety of two parenteral iron preparation in pregnant women with IDA. J Pharmacol. Pharmacother 2012; 3(4):314-319
8. Megha S, Akshay C, Bhadresh J, Kamlesh M et al. Intravenous iron sucrose therapy in pregnant and postpartum patients. Gujarat medical journal 2012; 67(1):57-60
9. iron product choice and dose calculation march 2016 www.blood.gov.au
10. Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant. 2005 Jul; 20(7): 1443-9.
11. Kuppuswamy's SES Scale for 2017 Online Tool.http://scaleupdate.weebly.com/
12. Rutherford J, Strong J. Anemia and White Blood Cell Disorder. In: James DK, Steer PJ, Weiner CP, Gonik B, editors. High risk pregnancy: management options. Philadelphila: Elsevier; 2006. pp. 865–88.
13. Turmen T, Abouzahr C. Safe motherhood. Int J Gynecol Obstet. 1994;46:145–53
14. Singh Subhadra, Singh Saroj, Singh Punit Kumar. A Study to Compare the Efficacy and Safety of Intravenous Iron Sucrose and Intramuscular Iron Sorbitol Therapy for Anemia during Pregnancy. The Journal of Obstetrics and Gynecology of India (January–February 2013) 63(1):18–21.
15. Suguna V et al. A Comparative Study on efficacy and safety of intravenous iron sucrose and intramuscular iron sorbitol in pregnancy anaemia. Sch. J. App. Med. Sci., September 2015; 3(6B):2301-2305.